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Abstract
Background: In order to achieve a safe and persistent angiogenic effect, we investigated the
potential of bone marrow cells implantation to enhance angiogenesis of ischemic hearts in a rat
model, and also we have investigated growth factors accompanying and intermediating the
angiogenesis, and the changes occurring in the levels of cytokines and their relations with
angiogenesis.
Methods: 30 adult male Wistar albino rats from the same colony were used. After anterior
myocardial infarction induced by occlusion of the left anterior descending artery, they were divided
into two groups (Group I and Group II). 2 × 107 bone marrow cells suspended in 0.1 ml phosphate-
buffered saline solution and 0.1 ml phosphate-buffered saline solution were injected at six points in
the infarcted area in Group I and Group II respectively. Changes in the vascular density and,
vascular endothelial growth factor, vascular cell adhesion molecule and cytokine levels in the
infarcted myocardium after bone marrow cells implantation were examined.
Results: The implantation assay showed that bone marrow cells induced angiogenesis. Light
microscopic analysis of the vascular density in the ischemic area showed that, angiogenesis had been
induced to higher in Group I than Group II. Levels of vascular endothelial growth factor, vascular
cell adhesion molecule and the inflammatory cytokines such as interleukin-1 and tumor necrosis
factor-α in Group I were significantly elevated compared with those in Group II.
Conclusion: Bone marrow cells implantation induced angiogenesis in a rat ischemic heart model
as a result of increase of the levels of vascular endothelial growth factor, vascular cell adhesion
molecule, interleukin-1, and tumor necrosis factor-α.
1. Introduction
Although medical therapy and coronary revascularization
techniques such as percutaneous balloon angioplasty and
stenting or surgical procedures improve the prognosis and
survey on coronary artery disease, a substantial number of
patients are failed despite maximal conventional therapy
because of not being suitable for coronary revasculariza-
tion. Improvement of neovascularization techniques
attenuates myocardial ischemia in coronary artery disease.
In order to promote neovascularization, several therapeu-
tic strategies have been developed including the addition
of angiogenic growth factors [1,2].
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Cell transplantation is a novel therapeutic option for
myocardial repair in hearts with postinfarction congestive
heart failure, unreconstructable coronary atherosclerosis,
or cardiomyopathy [3-5]. Implantation of nonselected
bone marrow cells into the ischemic myocardium has
been utilized to treat these patients. Bone marrow cells
provide angiogenic precursors and angiogenic cytokine-
producing cells in myocardium. Also, erythroid cells are
essential for the in vivo effects of bone marrow cell
implantation. In addition, bone marrow cells are a source
of multiple growth factors involved in neovascularization,
including vascular endothelial growth factor (VEGF).
Therapeutic angiogenesis describes an emerging field of
cardiovascular medicine whereby new blood vessel
growth is induced to supply oxygen and nutrients to
ischemic cardiac or skeletal muscle [6,7]. The growth of
this field has exploded in the past decade as a result of the
development of recombinant growth factors, the best
characterized of which is the soluble mediators' basic
fibroblast growth factor and VEGF. Both of these factors
stimulate in vivo angiogenesis [7,8], and numerous pre-
clinical studies utilizing protein therapy in a variety of ani-
mal models have demonstrated improvements in
perfusion, function, and vascularity [7,9].
Several chemokines and cytokines have been shown to
promote mobilization of hematopoietic stem cells and
endothelial progenitor cells. Mobilization by granulocyte-
colony stimulating factor is achieved by the disruption of
the homing mechanisms of stem cells in the bone mar-
row, e.g. by proteolytic cleavage of vascular cell adhesion
molecule (VCAM) [2,10]. Also, sVCAM has been reported
to exhibit angiogenic activity in vivo through mediating
endothelial cell chemotaxis activity [11]. In experimental
models, mobilization of stem cells was also achieved by
injections of chemokines such as interleukin-1 (IL-1β)
and tumor necrosis factor-α (TNF-α) [2,12-14].
In this study, we designed a rat myocardial ischemia
model to investigate the angiogenic ability of implanting
bone marrow cells in an acute myocardial infarction
model, and attempted to elucidate the possible mecha-
nism of neovascularization.
2. Materials and methods
2.1. Rats
30 adult male Wistar albino rats with an average of 200–
250 g body weight from the same colony were used. The
purpose of using rats is easy availability, safety and the
high ratio of repeating the experiment and because of
their minimal myocardial collaterals. The experiments
were conducted in accordance with the Guidelines for the
Care and Use of Laboratory Animals published by the
National Institutes of Health (NIH Publication No. 85-23,
revised 1996). They were kept at 21° to 23°C, with con-
trolled humidity, and a dark-light cycle of 12 to 12 h.
Food and water were available ad libitum. The experimen-
tal protocol was approved by Ataturk University, School
of Medicine, Animal Care and Use Committee.
2.2. Preparation of rat bone marrow cells
Randomly selected 5 rats were sacrificed and bone mar-
row from the femur and tibia was collected and a total of
4 ml of bone marrow blood was placed in phosphate-
buffered saline (PBS). Bone marrow cells were washed
twice in PBS and suspension was prepared through a fine
wire mesh. An optimal number of cells (2 × 107) were sus-
pended in 0.1 ml PBS.
2.3. Rat ischemic heart model
Rats were anesthetized with 50 mg/kg pentobarbital intra-
peritoneally. After tracheostomy, rats were entubed with
16G catheter. Rats were given ventilator support using
room atmosphere in volume control mode throughout
operation. 90/minute respiration count and 15–20 ml/kg
minute volume were provided during ventilation (Hugo
sacs, rodent ventilator, Germany). Reason of this, medias-
tinal pleura is not complete and is quite weak in rats.
Unless a positive pressure ventilation is achieved, pleura is
sutured and both lungs collapse even when only one
pleura is opened.
In operation, rats were put into right posterolateral posi-
tion; the site was shaved and disinfected by using povi-
done iodine. A left thoracotomy was performed through
the fourth intercostal space and the left anterior descend-
ing coronary artery (LAD) was ligated with 7.0 silk suture.
The rats were then randomly divided into two groups after
LAD ligation. In Group I (n = 12), the rats were injected,
at six points in the infarcted area using a 26-gauge needle
(2 × 107 bone marrow cells suspended in 0.1 ml PBS). In
Group II (n = 13, control group), the rats were injected, at
six points in the infarcted area using a 26-gauge needle
(0.1 ml PBS). Injections are made at the end of about a fif-
teen-minute-waiting-duration following the ligation of
LAD. The detection of infarcted area by the observation of
the discoloration formed in the left ventricular anterior
wall macroscopically. In general, it was determined that
the infarcted area was about 3 × 2 mm2and that the injec-
tion sites with a 1 mm distance among them were distrib-
uted homogenously throughout the infracted area. The
size of the infarcted area formed enables 6 different injec-
tion application points, and thus depending on the size of
infarcted area, direct intramyocardial injections were
applied from the six points of the infarcted area and bor-
dering zone. These injections were successfully performed
without any acute complication.Journal of Cardiothoracic Surgery 2008, 3:30 http://www.cardiothoracicsurgery.org/content/3/1/30
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Then, bleeding control was done, the lung was expanded
and thoracotomy incisions were closed properly. When
the spontaneous respiration was achieved, rats were
extubed, tracheostomy was closed and they were kept in
different cages. In the first 24 hours rats were given
Buprenorphine 0.03 mg/kg every 8 hours subcutaneously.
Antibiotic therapy with cefazolin sodium (15 mg/kg/
intramuscular) was given for 10 days. They were given
food and water as much as they wanted. Wound infection
developed in one rat (in Group II) and excluded from the
experiment protocol.
2.4. Changes in the levels of VEGF, IL-1β, sVCAM, and TNF-
α
On the 1st day after the operation, 2 rats both from the two
groups, on the 3rd day 2 rats both from the two groups and
on the 5th day 3 rats both from the two groups were sacri-
ficed by administering lethal Ketamine intraperitoneally.
The hearts were extracted and samples of the myocardial
infarct area were collected. All samples were minced and
homogenized in PBS on ice, then centrifuged at 10,000 g
for 5 min at 4°C, and the resulting supernatants were
stored at -80°C. Vascular endothelial growth factor
(VEGF), interleukin-1 (IL-1β), soluble vascular cell adhe-
sion molecule (sVCAM), and tumor necrosis factor-α
(TNF-α) in supernatant fluid were determined by a stand-
ard enzyme-linked immunoabsorbent assay method
(VEGF, IL-1β, sVCAM, and TNF-α ELISA kits, R&D sys-
tems, USA) according to the instructions of the manufac-
turers. The levels of these growth factors and cytokines
were expressed as picograms of VEGF, IL-1β, and TNF-α
and, as nanograms of sVCAM per tissue wet weight and
used for statistical analysis.
2.5. Evaluation of angiogenesis induced by the 
implantation of bone marrow cells
In the 1st week after the operation, 1 rat each both from
the two groups, in the 2nd week 2 rats each both from the
two groups, and in the 4th week 2 rats from Group I and 3
rats from Group II were sacrificed by administering lethal
Ketamine intraperitoneally. The hearts were extracted and
samples of the myocardial infarct area containing mar-
ginal and normal areas were embedded in OCT com-
pound, snap-frozen in liquid nitrogen, and cut into 5-µm-
thick sections. Tissue sections were immunostained with
mouse anti-rat CD31 monoclonal antibody using the
Dako LSAB 2 Kit, Peroxidase for use on rat specimens. The
sections were fixed with 99% acetone for 10 min at 4°C,
3% hydrogen peroxide was applied to cover each speci-
men to block endogenous peroxidase activity for 5 min.
The sections were incubated with mouse anti-rat CD31
antibody at 1:200 dilutions for 30 min at room tempera-
ture, and developed with 3.3'-diaminobenzidine plus
nickel sulfate in phosphate buffer-H2O2. Counterstaining
was performed with methyl green. Angiogenesis was
assessed by counting the number of vessels under light
microscopy. The entire infracted area was examined under
×200 microscopy to determine the mean number of ves-
sels per square millimeter.
2.6. Statistical analysis
The results were evaluated statistically. All data are pre-
sented as the mean ± standard error. One-way between-
groups analysis of variance (ANOVA) was used to com-
pare VEGF, IL-1β, sVCAM, and TNF-α between groups.
Statistically p > 0.05 was accepted as insignificant, and p <
0.05 as significant.
3. Results
In this study; neovascularization, as defined by density of
microvessels and VEGF, IL-1β, sVCAM, and TNF-α levels
in the infarcted myocardial tissues was quantified in the
Group I and Group II.
3.1. VEGF, sVCAM and cytokine levels in the infarcted 
myocardium after implantation of bone marrow cells
The changes in VEGF levels are shown in Fig 1. A signifi-
cantly higher VEGF level in the infarcted myocardial tis-
sues was observed in the Group I than Group II.
As shown in Fig 2 and Fig 3, the concentrations of IL-1β
and TNF-α in the infarcted myocardial tissues were signif-
icantly higher in the Group I than Group II.
Furthermore, the concentrations of sVCAM in the inf-
arcted myocardial tissues were also significantly higher in
the Group I than Group II (Fig 4).
Myocardial expressions of VEGF(61.1 ± 4.4 vs. 16.2 ± 3.4,
p < 0.01), IL-1β (1240.1 ± 12.1 vs. 213.2 ± 13.2, p < 0.01),
TNF-α (65.3 ± 4.5 vs. 2.1 ± 2.4, p < 0.01), and sVCAM
(156.3 ± 3.8 vs. 32.6 ± 4.2, p < 0.01) levels in implanta-
tion of bone marrow cells into the infarcted myocardial
tissues was significantly higher than that of Group II 5
days after treatment.
3.2. Determination of angiogenesis by histopathological 
examination
The numbers of vessels in per 5 square millimeter fields of
each histopathological preparation prepared separately
for each subject were calculated and in the end, individual
means of these values were found for each group. At the
end of the 1 week, the mean number of vessels in per 5
square millimeter fields was found to be 24.0 ± 4.2 in
Group I, and 13.3 ± 3.0 in Group II (p > 0.05). At the end
of the 2 weeks, the mean number of vessels in per 5 square
millimeter fields was found to be 46.4 ± 5.3 in Group I,
and 19.7 ± 3.4 in Group II (p < 0.05). And, at the end of
the 4 weeks, the mean number of vessels in per 5 squareJournal of Cardiothoracic Surgery 2008, 3:30 http://www.cardiothoracicsurgery.org/content/3/1/30
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millimeter fields was found to be 61.4 ± 5.6 in Group I,
and 23.2 ± 4.1 in Group II (p < 0.05).
In addition, angiogenesis was significantly increased in
the center of the scar in Group I compared to Group II. As
a result, the density of microvessels in the infarcted myo-
cardial tissues was significantly higher in Group I than
Group II, especially 2 and 4 weeks after the operation.
4. Discussion
In this experimental model, we demonstrated induced
myocardial angiogenesis as evidenced by increased micro-
vessels density. We observed that, intramyocardial
implantation of bone marrow cells induced angiogenesis.
Replacement and regeneration of functional cardiac mus-
cle after an ischemic insult to the heart could be achieved
by either stimulating proliferation of endogenous mature
cardiomyocytes, resident cardiac stem cells or by implant-
ing exogenous donor-derived or allogenic cardiomyo-
cytes. Angiogenesis was induced by the proliferation and
migration of endothelial cells from existing vessels in
adults [15-17]. A variety of growth factors are known to
induce angiogenesis. VEGF plays an important role in the
angiogenic process and promotes the proliferation and
migration of endothelial cells specifically [18-20]. In the
present study, we selected bone marrow cells as the mate-
rial for inducing angiogenesis because they contain
endothelial progenitor cells that can participate in vascu-
lar formation in severe ischemic lesions [21].
Bone marrow cells were considered optimal for implanta-
tion in this ischemic heart model. We found that a signif-
icant improvement in angiogenesis occurred within 2
weeks after implantation of bone marrow cells treatment.
The capillary density in the Group I was found to be sig-
nificantly increased 4 weeks after implantation of bone
marrow cells. In this time, bone marrow cells treatment
induced approximately 2.5-fold increase in capillary den-
sity as well.
Takahashi et al. reported that the implantation of bone
marrow cells into ischemic hearts can induce angiogenesis
by increasing the microvessel density and decreasing the
fibrotic area in the infarcted myocardium significantly
and improve cardiac function after myocardial infarction,
and concluded that various cytokines are produced by
bone marrow cells and these cytokines contributed to
Levels of VEGF* in the infracted myocardium after bone marrow cell implantation Figure 1
Levels of VEGF* in the infracted myocardium after bone marrow cell implantation. *The levels of VEGF, IL-1β, TNF-α (pg/mg) 
and sVCAM (ng/mg) in the restricted infracted myocardium per wet weight are indicated.Journal of Cardiothoracic Surgery 2008, 3:30 http://www.cardiothoracicsurgery.org/content/3/1/30
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functional improvement of the infarcted heart by directly
preserving the contractile capacity of the myocardium,
inhibiting apoptosis of cardiomyocytes, and inducing
therapeutic angiogenesis [22].
Recent studies have demonstrated that, the protein
expression of inflammatory cytokines, such as IL-1β and
cytocine-induced neutrophil chemoattractant, which have
been proven to have angiogenic potency in vivo, was sig-
nificantly increased in the implantation of bone marrow
cells group compared with the other groups [[19,23], and
[24]]. The main potential source for these inflammatory
cytokines is monocytes, macrophages, and granulocytes.
Bone marrow cells contain all these cells which have the
ability to release inflammatory cytokines. TNF-α that one
of the cytokines released from macrophages that induces
angiogenesis [14,25], was detectable in this model.
In a study carried out by Tse et al., autologous bone mar-
row cell implantation was applied into the 12 patients
with severe coronary artery disease who underwent elec-
tromechanical mapping-guided catheter-based. As a
result, they found that bone marrow cell implantation
into the ischemic human myocardium procedure is not
associated with long-term major adverse effects such as
tumor, scar, or calcification formation, and that the
arrhythmogenic risk is low [26].
Although implantation of bone marrow cells is an inva-
sive attempt, it increases the formation of microcapillary
arteries and collateral neovascularization in infracted
hearts, and improves ventricular heart function. Besides, it
proliferates and activates myocardial cells in infarcted
area. Thus, it decreases the infarct size and affects the
postinfarction remodeling beneficially. As a result, an
improvement in symptoms and exercise capacity, increase
in myocardial perfusion and function at the ischemic
myocardium occurs. Recently, this treatment protocol is
seen as a promising, safe, effective and feasible method in
ischemic heart diseases in terms of restoring tissue viabil-
ity and increasing functioning of patients. From the point
of effective administering way, Hayashi et al. found that
bone marrow cells are more effectively delivered intramy-
ocardially than intravenously for repairing injured myo-
cardium [27].
The present study is established that bone marrow cells
were effective for inducing therapeutic angiogenesis in a
rat acute myocardial infarction model, the mechanism of
which related to an increase in inflammatory cytokines,
such as IL-1β, TNF-α and sVCAM. The implantation of
Levels of IL-1β* in the infracted myocardium after bone marrow cell implantation Figure 2
Levels of IL-1β* in the infracted myocardium after bone marrow cell implantation. *: The levels of VEGF, IL-1β, TNF-α (pg/mg) 
and sVCAM (ng/mg) in the restricted infracted myocardium per wet weight are indicated.Journal of Cardiothoracic Surgery 2008, 3:30 http://www.cardiothoracicsurgery.org/content/3/1/30
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bone marrow cells is a simple method for inducing angio-
genesis without causing toxicity or immunological rejec-
tion, in comparison with other therapeutic methods of
angiogenesis using human recombinant protein, naked
plasmid DNA, and viruses. However, angiogenesis
induced by whole bone marrow cell implantation was not
dose dependent in this experiment, which may be
explained in two ways. First, whole bone marrow cells
consist of a variety of cells which may release a number of
growth factors or cytokines, including promotive and
inhibitive ones. Second, bone marrow cells may play a dif-
ferent role in the environment of ischemic myocardium or
acute infarcted myocardium, and it is possible that
stronger angiogenesis is induced by the implantation of
bone marrow cells in ischemic myocardium, where they
survive longer and are stimulated to secrete more ang-
iogenic factors such as VEGF. The ischemic environment
may facilitate the differentiation of endothelial progenitor
cells in bone marrow to endothelial cells. Further investi-
gations on implantation of bone marrow cells treatment
are required to clarify the optimal populations of whole
bone marrow cells that will have the most angiogenic
potency and to determine whether implantation of bone
marrow cells will induce stronger angiogenesis in an
ischemic environment.
In an experimental study similar to our study by Nishida
et al., it was found that bone marrow cell implantation
treatment in hypoperfusion heart model formed in rats
increased the microvessel density, blood flow and thick-
ness of the left ventricular anterior walls significantly. As a
result, they indicated that such an application induces
angiogenesis and improves the perfusion of ischemic
myocardium, and thereby prevents left ventricular remod-
eling and improves deteriorated cardiac function caused
by myocardial hypoperfusion, and all these findings are in
accordance with the results we obtained [28]. In general,
it is the infarct size that determines the long-term progno-
sis of the patients after myocardial infarction. Bone mar-
row cell implantation into ischemic heart can repair the
scar area and recover the myocardial function of the
patients and thus improve the life quality by means of the
above mentioned positive effects.
5. Conclusion
These results indicate that implantation of bone marrow
cells can successfully promote neovascularization using a
rat ischemic heart model. Also, the mechanism of this
effect seems to be related to an increase IL-1β, sVCAM,
and TNF-α. Our results proved that implantation of bone
marrow cells in the ischemic heart tissue is safe and effec-
tive and, has implications for clinical treatments of
Levels of TNF-α* in the infracted myocardium after bone marrow cell implantation Figure 3
Levels of TNF-α* in the infracted myocardium after bone marrow cell implantation. *: The levels of VEGF, IL-1β, TNF-α (pg/
mg) and sVCAM (ng/mg) in the restricted infracted myocardium per wet weight are indicated.Journal of Cardiothoracic Surgery 2008, 3:30 http://www.cardiothoracicsurgery.org/content/3/1/30
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patients with atherosclerotic coronary artery disease, and
"end stage" cardiac disease. When the improvement in liv-
ing comfort of the patients is taken into account, this
treatment protocol is a choice to be tried in necessary sit-
uations. Nevertheless, all these views should be arranged
in terms of the late period follow-up results to be obtained
from further randomized, controlled studies on human.
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